<DOC>
	<DOCNO>NCT01122979</DOCNO>
	<brief_summary>Primary Objective : &gt; To obtain estimation treatment group proportion patient reach target HbA1c &lt; = 7 % without confirm nocturnal hypoglycaemia treatment group . Secondary Objectives : - Glycemic control , measure HbA1c FPG ( fast plasma glucose ) baseline period treatment . - Incidence confirm symptomatic nocturnal hypoglycemia . - Incidence confirm severe hypoglycemia ( &lt; 36mg/dL need help recover ) . &gt; Weight variation period treatment . - Creatinine clearance baseline period treatment . - Overall safety : Incidence adverse event .</brief_summary>
	<brief_title>Evaluation Safety Efficacy Insulin Glargine + Glulisine Insulin Regular + NPH Insulin ( Isophane Insulin ) Use Type 2 Diabetes Mellitus Patients With Moderate Renal Failure .</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin glulisine</mesh_term>
	<mesh_term>Isophane insulin , beef</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<mesh_term>Isophane Insulin , Human</mesh_term>
	<mesh_term>Insulin , Isophane</mesh_term>
	<criteria>Inclusion criterion : Type 2 diabetes renal failure use NPH regular insulin fastacting analog HbA1c &gt; = 8 % . Albuminuria microalbuminuria diabetic retinopathy . Creatinine clearance &lt; 60 mL/min/1,73 m2 &gt; 30 mL/min/1,73 m2 Exclusion criterion : Hypersensibility insulin glargine component insulin formulation . Use investigational medication last 12 month use investigational insulin preparation last 4 month . History diabetic ketoacidosis positive GAD antibody . Advanced retinopathy need laser therapy . Diagnosed advanced neuropathy Severe hepatic disease active hepatitis . Cardiac failure class III IV ( NYHA ) . Patients hemodialysis . Diagnosed cancer . Active infection . Current therapy steroid . Patients recognize suspected endocrine disorder associate increased insulin resistance , acromegaly , hyperthyroidism . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>